Galectin Therapeutics Inc. (NASDAQ:GALT) shares shot up 6.3% during trading on Tuesday . The stock traded as high as $2.07 and last traded at $2.04, with a volume of 491,060 shares traded. The stock had previously closed at $1.92.

GALT has been the subject of several research reports. FBR & Co reaffirmed a “buy” rating on shares of Galectin Therapeutics in a report on Thursday, May 19th. HC Wainwright reaffirmed a “buy” rating on shares of Galectin Therapeutics in a report on Thursday, May 12th. Roth Capital assumed coverage on shares of Galectin Therapeutics in a report on Friday, July 1st. They set a “buy” rating on the stock. Finally, Zacks Investment Research raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Galectin Therapeutics presently has a consensus rating of “Buy” and an average price target of $8.58.

The firm has a 50 day moving average of $1.53 and a 200 day moving average of $1.43. The firm’s market cap is $59.12 million.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Tuesday, May 10th. The company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.07. On average, equities analysts forecast that Galectin Therapeutics Inc. will post ($0.97) EPS for the current fiscal year.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.